Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kangshuanyihao
- Development stage
- Unknown
- Lead developer
- Jiangsu Provincial Hospital of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
Kangshuanyihao (also known as Kangshuan No. 1) is a Traditional Chinese Medicine (TCM) formulation developed by the Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Provincial Hospital of Traditional Chinese Medicine). It is primarily investigated for its potential to reduce the "no-reflow" phenomenon in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). The formulation is thought to exert its therapeutic effects by modulating platelet function, reducing inflammatory responses, and improving vascular endothelial function. As a TCM product, it likely consists of a complex mixture of botanical extracts intended to address the multi-factorial mechanism of microvascular obstruction following coronary reperfusion.
- Brand names
- Kangshuanyihao
- Other names
- KangshuanyihaoKangshuan No. 1anti-embolization No. 1
02
Targets
NF-κBSIRT1 (NAD-dependent protein deacetylase sirtuin-1)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Kangshuanyihao.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kangshuanyihao.